Urinary bladder tuberculosis and Bacillus Calmette-Guérin instillation: Reduced efficacy of bisoprolol in hypertension;Tuberkulose durch Bacillus-Calmette-Guérin-instillation bei blasenkarzinom und hypertonie

Aktuelle Urologie

Volumn 41, Issue 6, 2010, Pages 372-374

  Drechsler, A ^a   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

bisoprolol efficacy; intravesical BCG instillation; rifampicin; tuberculosis; urinary bladder cancer

Indexed keywords

ANTIHYPERTENSIVE AGENT; BCG VACCINE; BISOPROLOL; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BLADDER DISEASE; BLADDER TUMOR; CASE REPORT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; ENZYME INDUCTION; HUMAN; HYPERTENSION; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; TRANSITIONAL CELL CARCINOMA; UROGENITAL TUBERCULOSIS;

AGED; ANTIHYPERTENSIVE AGENTS; ANTITUBERCULAR AGENTS; BCG VACCINE; BISOPROLOL; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; HUMANS; HYPERTENSION; MALE; RIFAMPIN; TUBERCULOSIS, UROGENITAL; URINARY BLADDER DISEASES; URINARY BLADDER NEOPLASMS;

EID: 78449244340     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-0030-1262676     Document Type: Article

References (15)

1. Babjuk M, Oosterlinck W, Sylvester R et al. Guidelines on non-muscle invasive bladder cancer. European Association of Urology, 2009 http: //www.uroweb.org/fileadmin/tx-eauguidelines/2009/Full/TaT1-BC.pdf (Stand: 29.03.2010)
2. Bennett P N., John V A., Whitmarsh V B. Effect of rifampicin on metoprolol and antipyrine kinetics. Br J Clin Pharmacol 1982 13 387-391
3. Böhle A, Suttmann H, Brandau S. Wirkmechanismen der intravesikalen BCG-Immuntherapie des oberfl̈chlichen Harnblasenkarzinoms. Urologe 2006 45 629-633
4. DiPaola R S., Lattime E C. Bacillus Calmette-Guerin Mechanism of Action: The role of immunity, apoptosis, necrosis and autophagy. J Urol 2007 178 1840-1841
5. Fachinformation Concor® COR 3,75mg. Merck Pharma GmbH
6. Fachinforamtion Eremfat® 600. Riemser Arzneimittel AG
7. Frickmann H, Jungblut S, Hanke P et al. Durch Bacillus Calmette-Guerin induzierte Tuberkulose. Pneumologie 2004 58 773-776
8. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001 276 14581-14587
9. Horikiri Y, Suzuki T, Mizobe M. Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans. J Pharm Sci 1998 87 289-294 (Pubitemid 28204580)
10. Niemi M, Backman J T., Fromm M F. et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003 42 819-850
11. Simon J, Finter G, Schnöller T et al. Intravesikale Therapie beim nicht muskelinvasiven Urothelkarzinom der Harnblase. Urologe 2009 48 1263-1272
12. Kirch W, Köhler H, Spahn H et al. Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet 1981 2 531-532
13. Kirch W, Milfersẗdt S, Halabi A et al. Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. Cardiovasc Drugs Ther 1990 4 487-491
14. Kirch W, Rose I, Klingmann I et al. Interaction of bisoprolol with cimetidine and rifampicin. Eur J Clin Pharmacol 1986 31 59-62
15. Westphal K, Weinbrenner A, Zschiesche M et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction. Clin Pharmacol Ther 2000 68 345-355